Wedbush Analysts Lift Earnings Estimates for Geron

Geron Co. (NASDAQ:GERN) – Investment analysts at Wedbush lifted their Q2 2025 earnings per share estimates for shares of Geron in a research report issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will earn ($0.02) per share for the quarter, up from their previous estimate of ($0.03). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.08) EPS.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The company had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Geron’s revenue for the quarter was up 12927.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.07) EPS.

GERN has been the topic of a number of other research reports. Barclays reaffirmed an “overweight” rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. Stifel Nicolaus reduced their price target on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Geron in a report on Wednesday, March 12th. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Geron in a report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Geron presently has an average rating of “Moderate Buy” and an average price target of $5.06.

Geron Price Performance

GERN stock opened at $1.20 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The firm has a market capitalization of $764.30 million, a P/E ratio of -3.75 and a beta of 0.76. The business’s 50-day moving average is $1.47 and its two-hundred day moving average is $2.69. Geron has a 1 year low of $1.17 and a 1 year high of $5.34.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in Geron during the 4th quarter worth approximately $28,000. Integrated Wealth Concepts LLC purchased a new position in Geron during the 4th quarter worth approximately $36,000. GF Fund Management CO. LTD. purchased a new position in Geron during the 4th quarter worth approximately $45,000. 111 Capital purchased a new position in Geron during the 4th quarter worth approximately $52,000. Finally, Fifth Lane Capital LP purchased a new position in Geron during the 4th quarter worth approximately $53,000. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.